Shamil Morayati, MD
Endocrinology, Diabetes & Metabolism · Burlington, NCNPI 1083631832
Payments from drug & device makers
Across 446 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Corcept Therapeutics$977
- Lilly USA, LLC$704
- AbbVie$701
- Amgen$542
- Sanofi-aventis U.S. LLC$478
- plus $3K from 33 others
What the payments were for
- Speaking & faculty fees$2373%
- Food & beverage$7,30097%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 75 | $1,118 |
| Corcept Therapeutics | 50 | $977 |
| Lilly USA, LLC | 42 | $704 |
| AbbVie | 48 | $701 |
| Amgen(2 entities) | 33 | $542 |
| Sanofi-aventis U.S. LLC | 21 | $478 |
| Merck | 22 | $328 |
| Amarin Pharma, Inc. | 16 | $273 |
| Boehringer Ingelheim | 14 | $237 |
| IBSA Pharma Inc. | 11 | $199 |
| Abbott | 10 | $192 |
| Arbor Pharmaceuticals, Inc. | 12 | $173 |
| Esperion Therapeutics, Inc. | 10 | $172 |
| AstraZeneca | 9 | $147 |
| Xeris Pharmaceuticals, Inc. | 8 | $138 |
| Insulet Corporation | 5 | $124 |
| Radius Health, Inc. | 7 | $121 |
| GSK | 6 | $87 |
| Shire North American Group Inc | 5 | $84 |
| Exact Sciences | 5 | $79 |
| Dexcom, Inc. | 4 | $78 |
| Amneal Pharmaceuticals LLC | 5 | $75 |
| Sanofi | 1 | $72 |
| Acella Pharmaceuticals, LLC | 4 | $72 |
| Medtronic(2 entities) | 4 | $65 |
| Mannkind Corporation | 3 | $41 |
| Pfizer | 2 | $34 |
| Irhythm Technologies, Inc. | 2 | $33 |
| Ultragenyx Pharmaceutical Inc. | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 2 | $27 |
| Ascendis Pharma Endocrinology Inc | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $20 |
| EUSA Pharma (US) LLC | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Boston Scientific | 1 | $13 |
| G Medical Diagnostic Services, Inc. | 1 | $13 |
How this compares
$7,549 in reported general payments places this provider in the 70th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 48 | $75,910 |
| ProliaDenosumab | 34 | $58,012 |
| JardianceEmpagliflozin | 35 | $40,727 |
| SynthroidLevothyroxine Sodium | 324 | $32,725 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $30,311 |
| TrulicityDulaglutide | 21 | $27,805 |
| GlyxambiEmpagliflozin/Linagliptin | 34 | $26,456 |
| FarxigaDapagliflozin Propanediol | 22 | $20,385 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $19,570 |
| EliquisApixaban | 14 | $18,608 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 12 | $17,906 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 20 | $16,397 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $16,180 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $11,642 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $10,462 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,118 | $82,52976 claims |
| Boehringer IngelheimJardiance, Glyxambi | $237 | $67,18369 claims |
| AmgenProlia | $542 | $58,01234 claims |
| MerckJanumet Xr, Janumet, Januvia | $328 | $42,93754 claims |
| AbbVieSynthroid, Armour Thyroid | $701 | $34,901350 claims |
| Lilly USA, LLCTrulicity | $704 | $27,80521 claims |
| AstraZenecaFarxiga | $147 | $20,38522 claims |
| PfizerEliquis | $34 | $18,60814 claims |
| GSKTrelegy Ellipta | $87 | $11,64218 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $75 | $61063 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Burlington
- Thomas OconnellBurlington$805K
- Anna SolumBurlington$29K
- Kathryn LucasMorehead City$37.9M
- Mark WarrenGreenville$5M
- Mary LawrenceMorehead City$4.9M
- John ParkerWilmington$4.1M
- John BuseChapel Hill$3.8M
- Wendy LaneAsheville$1.9M
- Anthony BarberHickory$1.4M
- Klara KleinChapel Hill$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.